Therapy Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Brentuximab vedotin Adcetris SGN-35 Adcetris (brentuximab vedotin) is an antibody-drug conjugate comprised of a monoclonal antibody targeting CD30 linked to the tubulin-binding drug MMAE, which binds CD30-expressing cells and disrupts microtubule polymerization, potentially resulting in decreased tumor growth (PMID: 22684302). Adcetris (brentuximab vedotin) is FDA approved for Hodgkin lymphoma, anaplastic large cell lymphoma, CD30-expressing mycosis fungoides, and in combination with chemotherapy in other CD30-expressing peripheral T-cell lymphomas (FDA.gov).
Dacarbazine Deticene Biocarbazine R Chemotherapy - Alkylating 14 Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle (NCI Drug Dictionary). Dacarbazine is FDA approved for melanoma (FDA.gov).
Doxorubicin Adriamycin Adria|ADR Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4 Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).
Vinblastine Velban
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Hodgkin's lymphoma not applicable Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine FDA approved Actionable In a Phase III trial that supported FDA approval, Adcetris (brentuximab vedotin) in combination with Deticene (dacarbazine), Adriamycin (doxorubicin), and Velban (vinblastine) resulted in an improved modified progression-free survival rate of 82.1% compared to 77.2% with the combination of Adriamycin (doxorubicin), Blenoxane (Bleomycin), Velban (vinblastine) and Deticene (dacarbazine) (HR=0.77, p=0.04) in patients with untreated stage III or IV Hodgkin's lymphoma (PMID: 29224502; NCT01712490). 29224502
Clinical Trial Phase Therapies Title Recruitment Status
NCT03712202 Phase II Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma Recruiting